Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China

Merck & Co.’s Keytruda is already the best-selling immuno-oncology drug on the market, but as one group of analysts sees it, the drug still has one key upside opportunity that’s not yet calculated into forecasts: the Chinese market.